Fig. 3

Enthesitis presences/relapse of resolved enthesitis (patients with LEI > 0/SPARCC > 0 at baseline). *Indicates a comparison where the 95% CI for tofacitinib does not overlap with the 95% CI for placebo. ^aEach site was assessed bilaterally, and results were combined. BID, twice daily; CI, confidence interval; LEI, Leeds Enthesitis Index; M, month; N, total number of patients with LEI > 0 or SPARCC > 0 in that particular location or number of affected sites at baseline; N1, total number of patients with LEI > 0 or SPARCC > 0 at baseline and with LEI = 0 or SPARCC = 0 at months 1 or 3; n, number of affected patients; SPARCC, Spondyloarthritis Research Consortium of Canada Enthesitis Index